Therapeutics: Biologicals for rheumatoid arthritis

BMJ (Online)

Volumn 343, Issue 7818, 2011, Pages

  Tugwell, Peter ^a   Singh, Jasvinder A ^b   Wells, George A ^c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL RESPONSE MODIFIER; CERTOLIZUMAB PEGOL; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

ARTICLE; BIOLOGICAL THERAPY; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DRUG MONITORING; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; INFECTION; LYMPHOMA; META ANALYSIS (TOPIC); MONOTHERAPY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW (TOPIC); TUBERCULOSIS; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION ROUTE; DRUG ANTAGONISM; DRUG COST; ECONOMICS; FEMALE; FORECASTING; MIDDLE AGED; QUALITY ADJUSTED LIFE YEAR;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION ROUTES; DRUG COSTS; DRUG MONITORING; FEMALE; FORECASTING; HUMANS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84858999548     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d4027     Document Type: Article

References (23)

1. National Institute for Health and Clinical Excellence. Rheumatoid arthritis. (Clinical guideline CG79.) 2010. http://guidance.nice.org.uk/CG79/ Guidance/.
2. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84. (Pubitemid 351847559)
3. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
4. Graudal N, Jürgens G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum 2010;62:2852-63.
5. Gaujoux-Viala C, Smolen JS, Landewe R, Dougados M, Kvien TK, Mola EM et al. Current evidence for the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:1004-9.
6. Katchamart W, Trudeau J, Phumethum V, Bombardier C. Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Cochrane Database Syst Rev 2010;4:CD008495.
7. Clinicaltrials.gov. Rheumatoid arthritis: comparison of active therapies in patients with active disease despite methotrexate therapy (RACAT). http://clinicaltrials.gov/ct2/show/ NCT00405275.
8. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009;4: CD007848.
9. Kievit W, Fransen J, Adang EM, den Broeder AA, Bernelot Moens HJ, Visser H, et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford) 2011;50:196-203.
10. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, MacDonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2010;10:CD008794.
11. Smolen JS, Aletaha D, Grisar JC, Stamm TA, Sharp JT. Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. Ann Rheum Dis 2010;69:1058-64.
12. Bucher C, Degen L, Dirnhofer S, Pless M, Herrmann R, Schraml P, Went P. Biologics in inflammatory disease: infliximab associated risk of lymphoma development. Gut 2005;54:732-3. (Pubitemid 40559270)
13. Delabaye I, de Keyser F, the REMITRACT study group. 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis. Arthritis Res Ther 2010;12:R121.
14. Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol 2010;47:187-98. (Review.)
15. Fransen J, van Riel P.L.C.M. The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 2005;23(suppl 39):S93-9. (Pubitemid 46657516)
16. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. ACR preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
17. Schoels M, Wong J, Scott DL, Zink A, Richards P, Landewé R, et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:996-1004.
18. Van der Velde G, Pham B, Machado M, Ieraci L, Witteman W, Bombardier C, et al. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. Arthritis Care and Research 2011;63:65-78.
19. Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev 2009;4:CD007277.
20. Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev 2009;1:CD005121.
21. Solomon DH, Avorn J, Katz JN, Weinblatt ME, Setoguchi S, Levin R, Schneeweiss S. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:3790-8. (Pubitemid 44955879)
22. Vandenbroucke JP. Benefits and harms of drug treatments. BMJ 2004;329:2-3. (Pubitemid 38869990)
23. Simon LS, Strand V, Boers M, Brooks PM, Henry D, Tugwell P. Observations from the OMERACT drug safety summit, May 2008. J Rheumatol 2009;36:2110-3.